S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Modern Day Options Trading For Beginners! (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Modern Day Options Trading For Beginners! (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Did You See These Trend Reversals? (Ad)pixel
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Modern Day Options Trading For Beginners! (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Modern Day Options Trading For Beginners! (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Did You See These Trend Reversals? (Ad)pixel
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Modern Day Options Trading For Beginners! (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Modern Day Options Trading For Beginners! (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Did You See These Trend Reversals? (Ad)pixel
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Modern Day Options Trading For Beginners! (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Modern Day Options Trading For Beginners! (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Did You See These Trend Reversals? (Ad)pixel
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
NYSE:RCUS

Arcus Biosciences - RCUS Stock Forecast, Price & News

$18.24
+0.78 (+4.47%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$17.55
$18.51
50-Day Range
$15.96
$23.15
52-Week Range
$15.70
$39.75
Volume
957,754 shs
Average Volume
1.25 million shs
Market Capitalization
$1.33 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.33

Arcus Biosciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
126.6% Upside
$41.33 Price Target
Short Interest
Healthy
14.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.59mentions of Arcus Biosciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$153,802 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.52) to ($3.51) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.21 out of 5 stars

Medical Sector

298th out of 1,004 stocks

Pharmaceutical Preparations Industry

130th out of 489 stocks


RCUS stock logo

About Arcus Biosciences (NYSE:RCUS) Stock

Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Receive RCUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RCUS Stock News Headlines

Unusual Passive Income Investment (Found on a Golf Course)
Marc reveals how anyone can get into a similar opportunity for just $5.
5 Hypergrowth Stocks to Buy Now
Luke Lango has found 14 stocks that have gone up over 1,000%. Now he’s named his top stocks for 2023. Just click to claim your copy. pixel
BTIG Keeps Their Buy Rating on Arcus Biosciences (RCUS)
SVB Securities Keeps Their Buy Rating on Arcus Biosciences (RCUS)
Truist Financial Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)
GSK Gears Up to Report Q4 Earnings: What's in the Cards?
See More Headlines
Receive RCUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RCUS Company Calendar

Last Earnings
11/08/2021
Today
4/01/2023
Next Earnings (Estimated)
5/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
366
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$41.33
High Stock Price Forecast
$51.00
Low Stock Price Forecast
$33.00
Forecasted Upside/Downside
+126.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Net Income
$-267,000,000.00
Net Margins
-237.26%
Pretax Margin
-237.50%

Debt

Sales & Book Value

Annual Sales
$112 million
Book Value
$9.07 per share

Miscellaneous

Free Float
63,739,000
Market Cap
$1.33 billion
Optionable
Optionable
Beta
0.89

Key Executives

  • Terry J. RosenTerry J. Rosen
    Chairman & Chief Executive Officer
  • Juan Carlos Jaen
    President & Director
  • Jennifer A. JarrettJennifer A. Jarrett
    Chief Operating Officer & Director
  • Robert C. GoeltzRobert C. Goeltz
    Chief Financial Officer
  • Steve Young
    Senior VP-Technology & Quantitative Biology













RCUS Stock - Frequently Asked Questions

Should I buy or sell Arcus Biosciences stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RCUS shares.
View RCUS analyst ratings
or view top-rated stocks.

What is Arcus Biosciences' stock price forecast for 2023?

9 brokerages have issued 12 month price targets for Arcus Biosciences' shares. Their RCUS share price forecasts range from $33.00 to $51.00. On average, they predict the company's stock price to reach $41.33 in the next twelve months. This suggests a possible upside of 126.6% from the stock's current price.
View analysts price targets for RCUS
or view top-rated stocks among Wall Street analysts.

How have RCUS shares performed in 2023?

Arcus Biosciences' stock was trading at $20.68 at the beginning of the year. Since then, RCUS stock has decreased by 11.8% and is now trading at $18.24.
View the best growth stocks for 2023 here
.

When is Arcus Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our RCUS earnings forecast
.

How were Arcus Biosciences' earnings last quarter?

Arcus Biosciences, Inc. (NYSE:RCUS) released its quarterly earnings results on Monday, November, 8th. The company reported ($1.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.13) by $0.02. The firm had revenue of $9.46 million for the quarter, compared to analysts' expectations of $9.27 million. Arcus Biosciences had a negative trailing twelve-month return on equity of 36.77% and a negative net margin of 237.26%. During the same period in the prior year, the company posted $0.03 earnings per share.

What is Terry Rosen, Ph.D.'s approval rating as Arcus Biosciences' CEO?

4 employees have rated Arcus Biosciences Chief Executive Officer Terry Rosen, Ph.D. on Glassdoor.com. Terry Rosen, Ph.D. has an approval rating of 100% among the company's employees. This puts Terry Rosen, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Arcus Biosciences own?
When did Arcus Biosciences IPO?

(RCUS) raised $99 million in an initial public offering on Thursday, March 15th 2018. The company issued 7,100,000 shares at $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners served as the underwriters for the IPO.

What is Arcus Biosciences' stock symbol?

Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."

How do I buy shares of Arcus Biosciences?

Shares of RCUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcus Biosciences' stock price today?

One share of RCUS stock can currently be purchased for approximately $18.24.

How much money does Arcus Biosciences make?

Arcus Biosciences (NYSE:RCUS) has a market capitalization of $1.33 billion and generates $112 million in revenue each year. The company earns $-267,000,000.00 in net income (profit) each year or ($3.72) on an earnings per share basis.

How many employees does Arcus Biosciences have?

The company employs 366 workers across the globe.

How can I contact Arcus Biosciences?

Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The official website for the company is www.arcusbio.com. The company can be reached via phone at (510) 694-6200 or via email at investorinfo@arcusbio.com.

This page (NYSE:RCUS) was last updated on 4/1/2023 by MarketBeat.com Staff